NCT05052723CompletedPhase 2
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 12 Sept 2021
- Start date
- 4 Jan 2022
- Primary completion date
- 5 Nov 2024
- Lead sponsor
- Joseph Kim
- Diseases
- Pancreatic cancer
- NCT number
- NCT05052723
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 21
- From 4 Jan 2022 to the primary completion date, 5 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
- Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
- Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
Other illness
- Clinically significant cardiovascular disease
- Uncontrolled hypertension
Other
- Inability to swallow tablets
Who the study is looking for
- Diagnosis of pancreatic ductal adenocarcinoma
- Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
- Patients must have adequate organ function
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kentucky/Markey Cancer Center Coordinator of this site? Confirm its status | Lexington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.